Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Prolaris® (CCP Score)

Prolaris measures the expression of cell cycle progression (CCP) genes to assess prostate cancer aggressiveness.

Evidence-based context for fast calculator use

Purpose:
Prolaris CCP Score assesses prostate cancer aggressiveness via cell cycle gene expression to guide active surveillance or treatment decisions.
Population:
patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment
Factors:
Prolaris CCP Score, NCCN/Clinical Risk Category
Reference:
Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245-255.
HomeProlaris® (CCP Score)
Pin your most used calculators here by clicking the star in the dropdown.

Prolaris® (CCP Score)

Clinical Context & Background

Prolaris measures the expression of cell cycle progression (CCP) genes to assess prostate cancer aggressiveness. The result is typically reported as a CCP Score (ranging from -3 to +3) and a Combined Clinical Risk (CCR) score which predicts the 10-year risk of prostate cancer-specific mortality or metastasis.
Primary Source EvidenceCuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245-255.
Formula Logic
Interpretation of CCP Score / CCR.

Reference Data

CCR ScoreRisk ProfileManagement
LowLess AggressiveActive Surveillance may be appropriate.
HighMore AggressiveMultimodal therapy often considered.

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Prolaris® (CCP Score) when prolaris CCP Score assesses prostate cancer aggressiveness via cell cycle gene expression to guide active surveillance or treatment decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low through High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm biopsy versus prostatectomy setting, PSA timing, grade group, clinical/pathologic stage, imaging, life expectancy, and treatment history.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Diagnostic, post-prostatectomy, genomic, and recurrence tools must be used only at their intended decision point.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment

How to apply this result

For a representative case, verify Prolaris CCP Score, NCCN/Clinical Risk Category, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Prostate Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

D'Amico Risk ClassificationEpstein Criteria (Insignificant Cancer)PI-RADS™ v2.1 (Prostate MRI)

Frequently Asked Questions

When should Prolaris® (CCP Score) be used?

Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.

Can Prolaris® (CCP Score) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.